PM&R
Volume 2, Issue 5 , Pages 399-405 , May 2010

Central and Peripheral Fatigue: Exemplified by Multiple Sclerosis and Myasthenia Gravis

Received 7 December 2009 ,Accepted 15 April 2010.

References 

  1. Schwid SR, Thornton CA, Pandya S, et al. Quantitative assessment of motor fatigue and strength in MS. Neurology. 1999;53:743–750
  2. Schwid SR, Tyler CM, Scheid EA, Weinstein A, Goodman AD, McDermott MP. Cognitive fatigue during a test requiring sustained attention: a pilot study. Mult Scler. 2003;9:503–508
  3. Bergamaschi R, Romani A, Versino M, Poli R, Cosi V. Clinical aspects of fatigue in multiple sclerosis. Funct Neurol. 1997;12:247–251
  4. Kurtzke JF. Historical and clinical perspectives of the expanded disability status scale. Neuroepidemiology. 2008;31:1–9
  5. Pellicano C Gallo A, Li X, et al. Cortical atrophy is related to fatigue in patients with multiple sclerosis. Arch Neurol. In press.
  6. Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler. 2003;9:219–227
  7. Rosenberg JH SR. Fatigue in multiple sclerosis: A rational approach to evaluation and treatment. Curr Neurol Neurosci Rep. 2005;5:140–146
  8. Humm AM, Beer S, Kool J, Magistris MR, Kesselring J, Rosler KM. Quantification of Uhthoff's phenomenon in multiple sclerosis: A magnetic stimulation study. Clin Neurophysiol. 2004;115:2493–2501
  9. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis. Washington, DC: Paralyzed Veterans of America; 1998;
  10. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002;72:179–183
  11. El-Moslimany H, Lublin FD. Clinical features in multiple sclerosis. In:  Raine CS,  McFarland HF,  Hohlfeld R editor. Edinburgh: Saunders/Elsevier; 2008;
  12. Greim B, Benecke R, Zettl UK. Qualitative and quantitative assessment of fatigue in multiple sclerosis (MS). J Neurol. 2007;254(Suppl 2):II58–II64
  13. Koch M, Mostert J, Heerings M, Uyttenboogaart M, De Keyser J. Fatigue, depression and disability accumulation in multiple sclerosis: A cross-sectional study. Eur J Neurol. 2009;16:348–352
  14. Logsdon RG, Teri L. Depression in Alzheimer's disease patients: Caregivers as surrogate reporters. J Am Geriatr Soc. 1995;43:150–155
  15. Brass SD, Duquette P, Proulx-Therrien J, Auerbach S. Sleep disorders in patients with multiple sclerosis. Sleep Med Rev. 2009;14:121–129
  16. Fleming WE, Pollak CP. Sleep disorders in multiple sclerosis. Semin Neurol. 2005;25:64–68
  17. Johns MW. A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep. 1991;14:540–545
  18. Strober LB, Arnett PA. An examination of four models predicting fatigue in multiple sclerosis. Arch Clin Neuropsychol. 2005;20:631–646
  19. Colombo N, Boneschi F, Rossi P, et al. MRI and motor evoked potential findings in nondisabled multiple sclerosis patients with and without symptoms of fatigue. J Neurol. 2000;247:506–509
  20. Bakshi RMR, Kinkel PR, Emmet ML, Kinkel WR. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging. 1998;8:228–234
  21. Roelke U, Kappos L, Lechner-Scott J. Reduced glucose metabolism in frontal cortex of basal ganglia of multiple sclerosis patients with fatigue. Neurology. 1997;48:1566–1571
  22. Filippi M, Rocca MA, Colombo B, et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage. 2002;15:559–567
  23. Marrie RA, Fisher E, Miller D, Lee J-C, Rudick R. Association of fatigue and brain atrophy in multiple sclerosis. J Neurol Sci. 2005;228:161–166
  24. Tartaglia MC, Narayanan S, Arnold DL. Mental fatigue alters the pattern and increases the volume of cerebral activation required for a motor task in multiple sclerosis patients with fatigue. Eur J Neurol. 2008;15:413–419
  25. Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. Lancet Neurol. 2008;7:841–851
  26. Smith KJ. Conduction properties of central demyelinated and remyelinated axons and their relation to symptom production in demyelinating disorders. Eye. 1994;8:224–237
  27. Kocis J, Waxman SG. Neurophysiology of demyelination. In:  Raine C,  McFarland HF,  Hohlfeld R editor. Multiple Sclerosis. New York: Saunders; 2008;p. 178–191
  28. Rasminsky M. The effects of temperature on conduction in demyelinated single nerve fibers. Arch Neurol. 1973;28:287–292
  29. Hautecoeur P, Forzy G, Gallois P, Demirbilek V, Feugas O. Variations of IL2, IL6, TNF alpha plasmatic levels in relapsing remitting multiple sclerosis. Acta Neurol Belg. 1997;97:240–243
  30. Heesen C, Nawrath L, Reich C, Bauer N, Schulz KH, Gold SM. Fatigue in multiple sclerosis: An example of cytokine mediated sickness behaviour?. J Neurol Neurosurg Psychiatry. 2006;77:34–39
  31. Flachenecker P, Bihler I, Weber F, Gottschalk M, Toyka KV, Rieckmann P. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler. 2004;10:165–169
  32. Khademi M, Stol D, Olsson T, Wallstrom E. Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis. Eur J Neurol. 2008;15:309–312
  33. Gayo A, Mozo L, Suarez A, Tunon A, Lahoz C, Gutierrez C. Interferon beta-1b treatment modulates TNFalpha and IFNgamma spontaneous gene expression in MS. Neurology. 1999;52:1764–1770
  34. Greim B, Engel C, Apel A, Zettl UK. Fatigue in neuroimmunological diseases. J Neurol. 2007;254(Suppl 2):II102–II106
  35. Davis MC, Zautra AJ, Younger J, Motivala SJ, Attrep J, Irwin MR. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun. 2008;22:24–32
  36. Anisman H, Merali Z. Cytokines, stress and depressive illness: Brain-immune interactions. Ann Med. 2003;35:2–11
  37. Giovannoni G. Multiple sclerosis related fatigue. J Neurol Neurosurg Psychiatry. 2006;77:2–3
  38. Gottschalk M, Kumpfel T, Flachenecker P, et al. Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol. 2005;62:277–280
  39. Lebrun C, Alchaar H, Candito M, Bourg V, Chatel M. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler. 2006;12:321–324
  40. Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci. 2004;218:103–108
  41. Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: A systematic review. J Adv Nurs. 2006;56:617–635
  42. Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler. 2002;8:161–168
  43. Di Fabio RP, Soderberg J, Choi T, Hansen CR, Schapiro RT. Extended outpatient rehabilitation: Its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. Arch Phys Med Rehabil. 1998;79:141–146
  44. Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev. 2005;CD003980
  45. Grahn DA, Murray JV, Heller HC. Cooling via one hand improves physical performance in heat-sensitive individuals with multiple sclerosis: A preliminary study. BMC Neurol. 2008;8:14
  46. Nilsagard Y, Denison E, Gunnarsson LG. Evaluation of a single session with cooling garment for persons with multiple sclerosis–a randomized trial. Disabil Rehabil Assist Technol. 2006;1:225–233
  47. Branas P, Jordan R, Fry-Smith A, Burls A, Hyde C. Treatments for fatigue in multiple sclerosis: A rapid and systematic review. Health Technol Assess. 2000;4:1–61
  48. Lee D, Newell R, Ziegler L, Topping A. Treatment of fatigue in multiple sclerosis: A systematic review of the literature. Int J Nurs Pract. 2008;14:81–93
  49. Judge SI, Bever CT. Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther. 2006;111:224–259
  50. Van Lunteren E, Moyer M, Pollarine J. Long-lasting in vivo inotropic effects of the K(+) channel blocker 3,4-diaminopyridine during fatigue-inducing stimulation. Muscle Nerve. 2008;38:1616–1622
  51. Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study. Neurology. 2005;64:1139–1143
  52. Littleton ET, Hobart JC, Palace J. Modafinil for multiple sclerosis fatigue: Does it work?. Clin Neurol Neurosurg. 2009;112:29–31
  53. Schwid SR, Murray TJ. Treating fatigue in patients with MS: One step forward, one step back. Neurology. 2005;64:1111–1112
  54. Schwid SR, Covington M, Segal BM, Goodman AD. Fatigue in multiple sclerosis: Current understanding and future directions. J Rehabil Res Dev. 2002;39:211–224
  55. Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev. 2008;CD006264
  56. Humm AM, Z'Graggen WJ, Buhler R, Magistris MR, Rosler KM. Quantification of central motor conduction deficits in multiple sclerosis patients before and after treatment of acute exacerbation by methylprednisolone. J Neurol Neurosurg Psychiatry. 2006;77:345–350
  57. Symonette CJ, Watson BV, Koopman WJ, Nicolle MW, Doherty TJ. Muscle strength and fatigue in patients with generalized myasthenia gravis. Muscle Nerve. 2009;41:362–369
  58. Kinali M, Beeson D, Pitt MC, et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol. 2008;201–2026-12
  59. Engel AG. Neuromuscular manifestations of Graves' disease. Mayo Clin Proc. 1972;47:919–925
  60. Lucchi M, Ricciardi R, Melfi F, et al. Association of thymoma and myasthenia gravis: oncological and neurological results of the surgical treatment. Eur J Cardiothorac Surg. 2009;35:812–816discussion 816
  61. Gilhus NE. Autoimmune myasthenia gravis. Expert Rev Neurother. 2009;9:351–358
  62. Sanders DB. The electrodiagnosis of myasthenia gravis. Ann N Y Acad Sci. 1987;505:539–556
  63. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis (Prevalence, clinical correlates, and diagnostic value). Neurology. 1976;26:1054–1059
  64. Matsui M, Wada H, Ohta M, Kuroda Y. Potential role of thymoma and other mediastinal tumors in the pathogenesis of myasthenia gravis. J Neuroimmunol. 1993;44:171–176

 Disclosure Key can be found on the Table of Contents and at www.pmrjournal.org

PII: S1934-1482(10)00332-1

doi: 10.1016/j.pmrj.2010.04.012

PM&R
Volume 2, Issue 5 , Pages 399-405 , May 2010

Article Tools